Country for PR: United States
Contributor: PR Newswire New York
Tuesday, December 01 2020 - 02:00
Population Council and Duchesnay Announce New International License Agreement for ANNOVERA(R)
NEW YORK and BLAINVILLE, QC, Nov. 30, 2020 /PRNewswire-AsiaNet/--

Today the Population Council and Duchesnay announce an exclusive license 
agreement to make ANNOVERA(R) (segesterone acetate and ethinyl estradiol 
vaginal system), the first and only contraceptive fully under a woman's control 
to protect against unintended pregnancy for up to a year, available in Canada, 
Europe, Latin America, Asia and other territories. This agreement is another 
step toward bringing contraceptive choice, convenience and control to women 
around the world. 

ANNOVERA is the first in a new class of contraceptives. It is a soft reusable 
flexible silicone ring that combines a novel progestin Nestorone(R) 
(segesterone acetate) with a widely used estrogen (ethinyl estradiol), that can 
be inserted and removed by a woman herself. ANNOVERA was approved by the U.S. 
Food and Drug Administration (FDA) in August 2018 and is now available to women 
in the United States.  

"A lack of longer-lasting, women-controlled contraceptives means too many women 
who want to avoid pregnancy either don't use, or stop using, contraception, 
leading to more unintended pregnancies and worse health outcomes," said Jim 
Sailer ( 
), vice president and executive director of the Center for Biomedical Research 
) at the Population Council. "This agreement will now open up opportunities to 
bring ANNOVERA to women on four continents-it's another step forward in 
ensuring that women around the world have the contraceptive choices they 

ANNOVERA was developed by the Population Council and supported by important 
public and private donors from around the world, including the United States 
Agency for International Development (USAID), The Contraceptive Clinical Trials 
Network of the Eunice Kennedy Shriver National Institute of Child Health and 
Human Development (NICHD), the Bill & Melinda Gates Foundation, the Avis and 
Clifford Barrus Medical Foundation and the World Health Organization (WHO).

As part of the agreement, Duchesnay will explore opportunities to register 
ANNOVERA with local regulatory agencies in these regions and will invest in the 
Population Council's research activities to develop new innovative 
contraceptive products.

"We are very excited to be a part of the Population Council's efforts to bring 
important new contraceptive options to women around the world. As a company 
committed to improving women's health, we believe that women deserve access to 
a wide variety of innovative contraceptive options such as ANNOVERA giving them 
full control of their lives," said Eric Gervais, executive vice president at 

About the Population Council
The Population Council confronts critical health and development issues-from 
stopping the spread of HIV to improving reproductive health and ensuring that 
young people lead full and productive lives. Through biomedical, social 
science, and public health research in 50 countries, we work with our partners 
to deliver solutions that lead to more effective policies, programs, and 
technologies that improve lives around the world. Established in 1952 and 
headquartered in New York, the Council is a nongovernmental, non-profit 
organization governed by an international board of trustees. 

Learn more at 

About Duchesnay 
Duchesnay is a specialty pharmaceutical company with a long-standing commitment 
to women's health. Until recently, the company focused on filling the void in 
terms of scientific research and education and on developing pharmacological 
solutions that are safe and effective for use during pregnancy and 

Today, Duchesnay has broadened its portfolio of products to offer safe and 
effective therapeutic options that meet the health and quality of life needs of 
women and their family members at different stages of their lives.

For more information about Duchesnay, please visit:

Contact: Dominique Touchette

SOURCE:  Duchesnay inc.